How Many Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s Analysts Are Bullish?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Logo
Investors sentiment increased to 1.37 in 2019 Q1. Its up 0.30, from 1.07 in 2018Q4. It increased, as 16 investors sold Ironwood Pharmaceuticals, Inc. shares while 38 reduced holdings. 30 funds opened positions while 44 raised stakes. 146.70 million shares or 4.31% more from 140.64 million shares in 2018Q4 were reported.
Prudential Finance holds 0% or 12,884 shares. Hbk Investments L P reported 225,100 shares or 0.04% of all its holdings. Proshare Advsrs Limited Liability Company accumulated 0.01% or 67,830 shares. United Service Automobile Association has invested 0.01% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Westfield Cap Management Com L P owns 0.19% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 1.88M shares. 89,266 were reported by State Board Of Administration Of Florida Retirement Systems. Zurcher Kantonalbank (Zurich Cantonalbank), Switzerland-based fund reported 8,452 shares. Td Asset Mgmt reported 47,017 shares stake. Cwm Ltd Liability Company holds 2,974 shares or 0% of its portfolio. State Of Wisconsin Board accumulated 187,700 shares. Millennium Mgmt Ltd Liability Com has invested 0.02% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Northern Tru owns 1.75M shares or 0.01% of their US portfolio. Deutsche Commercial Bank Ag holds 796,204 shares or 0.01% of its portfolio. Bridger Ltd has invested 4.48% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Quantitative Investment Mngmt Limited Liability Com, Virginia-based fund reported 50,800 shares.

Since January 23, 2019, it had 0 buys, and 1 sale for $1.12 million activity.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

Among 5 analysts covering Ironwood Pharmaceuticals (NASDAQ:IRWD), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. Ironwood Pharmaceuticals had 9 analyst reports since January 24, 2019 according to SRatingsIntel. The firm has “Equal-Weight” rating given on Wednesday, March 27 by Morgan Stanley. H.C. Wainwright upgraded Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rating on Monday, February 25. H.C. Wainwright has “Neutral” rating and $14 target. The firm earned “Hold” rating on Monday, June 24 by H.C. Wainwright. The rating was maintained by Mizuho on Friday, February 22 with “Buy”. JP Morgan upgraded the stock to “Neutral” rating in Thursday, January 24 report. Credit Suisse maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Friday, March 22 with “Hold” rating. Below is a list of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) latest ratings and price target changes.

10/07/2019 Broker: Inc. – Class A Common Stock Rating: Credit Suisse
24/06/2019 Broker: H.C. Wainwright Rating: Hold New Target: $13 Maintain
17/04/2019 Broker: BidaskScore Rating: Sell Downgrade
27/03/2019 Broker: Morgan Stanley Old Rating: Underweight New Rating: Equal-Weight Old Target: $11 New Target: $14 Upgrade
22/03/2019 Broker: Credit Suisse Rating: Hold New Target: $16 Maintain
26/02/2019 Broker: BidaskScore Rating: Hold Downgrade
25/02/2019 Broker: H.C. Wainwright Old Rating: Sell New Rating: Neutral Old Target: $11.5 New Target: $14 Upgrade
22/02/2019 Broker: Mizuho Rating: Buy New Target: $18 Maintain
24/01/2019 Broker: JP Morgan Old Rating: Underweight New Rating: Neutral Old Target: $11 New Target: $13 Upgrade

The stock decreased 0.10% or $0.01 during the last trading session, reaching $10.46. About 785,249 shares traded. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has declined 36.78% since July 14, 2018 and is downtrending. It has underperformed by 41.21% the S&P500.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $1.63 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

More notable recent Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news were published by: Seekingalpha.com which released: “Ironwood advancing Cyclerion spinoff – Seeking Alpha” on January 28, 2019, also Nasdaq.com with their article: “Why Is Ironwood (IRWD) Up 6.9% Since Last Earnings Report? – Nasdaq” published on June 01, 2019, Bizjournals.com published: “Ironwood co-founder, CEO will step down to head new spinout – Boston Business Journal” on January 04, 2019. More interesting news about Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) were released by: Bizjournals.com and their article: “Cambridge’s Ironwood Pharma moving HQ to downtown Boston – Boston Business Journal” published on June 13, 2019 as well as Seekingalpha.com‘s news article titled: “Allergan and Ironwood settle Linzess patent litigation with Mylan – Seeking Alpha” with publication date: January 02, 2019.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.